Can-Fite BioPharma discloses $8.3 million warrant offering in SEC Form D filing

Can-Fite BioPharma Ltd., based in Ramat Gan, Israel, filed a Form D with the Securities and Exchange Commission dated September 10, 2026, disclosing a new exempt securities offering. The filing lists a date of first sale of September 2, 2026.¹

The offering covers warrants issued on September 3, 2026. The Form D covers warrants issued that day, including investor warrants totaling 3,183,476 shares at $2.50 per share and placement agent warrants totaling 111,422 shares at $3.125 per share.¹ The filing excludes exercise of warrants issued in March 2026, and states that the total offering amount equals the exercise price of the new warrants if exercised in full.¹

The total offering amount and total amount sold are both listed as $8,306,884, with $0 remaining to be sold.¹ The company reported one investor who has already invested in the offering.¹

The offering claims exemption under Rule 506(b) of Regulation D.¹ H.C. Wainwright & Co., LLC is listed as a sales compensation recipient, based in New York.¹ Sales commissions are estimated at $278,554, described as a 7% cash fee plus 1% management fee to H.C. Wainwright on warrant exercise proceeds, along with $25,000 in non-accountable expenses and $50,000 in accountable expenses, with HCW agent warrants included elsewhere in the filing.¹

On planned use of proceeds, the company stated it expects to use any proceeds for funding research and development and clinical trials, along with other working capital and general corporate purposes, and that no proceeds are expected to be paid to executive officers, directors, or promoters.¹

The filing was signed by Motti Farbstein, Chief Executive Officer, on September 10, 2026.¹